Depletion of biotin using streptavidin-coated microparticles: a validated solution to the problem of biotin interference in streptavidin–biotin immunoassays

Annals of Clinical Biochemistry

Volumn 55, Issue 2, 2018, Pages 216-226

  Trambas, Christina ^a   Lu, Zhong ^a,b   Yen, Tina ^a,c   Sikaris, Ken ^a  

^a MELBOURNE PATHOLOGY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Evaluation of new methods; immunoassay; laboratory methods

Indexed keywords

BIOTIN; LIOTHYRONINE; STREPTAVIDIN; STREPTAVIDIN COATED MAGNETIC MICROPARTICLE; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROXINE; UNCLASSIFIED DRUG; BIOCOMPATIBLE COATED MATERIAL;

ANTIBODY BLOOD LEVEL; ARTICLE; COMPETITIVE IMMUNOASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEPLETION; DRUG MEGADOSE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HUMAN; HUMAN TISSUE; IMMUNOASSAY; INCUBATION TIME; LABORATORY TECHNIQUE; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SANDWICH IMMUNOASSAY; SERUM; THYROID FUNCTION TEST; ARTIFACT; BLOOD; CHEMISTRY; ISOLATION AND PURIFICATION; PATHOPHYSIOLOGY; PROCEDURES; STANDARDS; VALIDATION STUDY;

ARTIFACTS; BIOTIN; CLINICAL LABORATORY TECHNIQUES; COATED MATERIALS, BIOCOMPATIBLE; HUMANS; IMMUNOASSAY; MULTIPLE SCLEROSIS; STREPTAVIDIN; THYROID FUNCTION TESTS;

EID: 85029942499     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563217707783     Document Type: Article

References (25)

1. Henry JG, Sobki S, Arafat N. Interference by biotin therapy on measurement of TSH and FT4 by enzyme immunoassay on Boehringer Mannheim ES700 analyser. Ann Clin Biochem 1996; 33: 162–163.
2. Kwok JS, Chan IH, Chan MH. Biotin interference on TSH and free thyroid hormone measurement. Pathology 2012; 44: 278–280.
3. Wijeratne NG, Doery JC, Lu ZX. Positive and negative interference in immunoassays following biotin ingestion: a pharmacokinetic study. Pathology 2012; 44: 674–675.
4. Seaborg, E. Thyroid month: beware of biotin. Endocrine Society Endocrine News, January 2016, http://endocrinenews.endocrine.org/january-2016-thyroid-month-beware-of-biotin/ (accessed 15 March 2016)
5. Barbesino G. Misdiagnosis of Graves' disease with apparent severe hyperthyroidism in a patient taking biotin megadoses. Thyroid 2016; 26: 860–863.
6. Trambas CM, Sikaris KA, Lu ZX. More on biotin treatment mimicking Graves' disease. N Engl J Med 2016; 375: 1698–1698.
7. Elston MS, Seghal S, Du Toit S, Factitious Graves’ Disease due to biotin immunoassay interference – a case and review of the literature. J Clin Endocrinol Metab 2016; 101: 3251–3255.
8. Kummer S, Hermsen D, Distelmaier F. Biotin treatment mimicking Graves' disease. N Engl J Med 2016; 375: 704–706.
9. Piketty ML, Polak M, Flechtner I, False biochemical diagnosis of hyperthyroidism in streptavidin-biotin-based immunoassays: the problem of biotin intake and related interferences. Clin Chem Lab Med. Epub ahead of print 1 November 2016 doi: 10.1515/cclm-2016-0606.
10. Minkovsky A, Lee MN, Dowlatshahi M, High-dose biotin treatment for secondary progressive multiple sclerosis may interfere with thyroid assays. AACE Clin Case Rep 2016; 2: e370–e373.
11. Bülow Pedersen I, Laurberg P. Biochemical hyperthyroidism in a newborn baby caused by assay interaction from biotin intake. Eur Thyroid J 2016; 5: 212–215.
12. Trambas CM, Sikaris KA, Lu ZX. A caution regarding high-dose biotin therapy: misdiagnosis of hyperthyroidism in euthyroid patients. Med J Aust 2016; 205: 192–192.
13. Waghray A, Milas M, Nyalakonda K, Falsely low parathyroid hormone secondary to biotin interference: a case series. Endocr Pract 2013; 19: 451–455.
14. Tate J, Ward G. Interferences in Immunoassay. Clin Biochem Rev 2004; 25: 105–120.
15. Peyro Saint Paul L, Debruyne D, Bernard D, Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis. Expert Opin Drug Metab Toxicol 2016; 12: 327–344.
16. RCPA Guideline. The ethical and legal issues in relation to the use of human tissue and test results in Australia. Surry Hills, NSW, Australia: Royal Australasian College of Pathologists, 2010.
17. Trambas CM, Lu ZX, Yen T, Characterisation of the scope and magnitude of biotin interference in Roche competitive and sandwich immunoassays. Ann Clin Biochem. In press. DOI: 10.1177/0004563217701777.
18. Sedel F, Papeix C, Bellanger A, High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord 2015; 4: 159–169.
19. Tourbah A, Lebrun-Frenay C, Edan G, MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study. Mult Scler 2016; 22: 1719–1731.
20. Zempleni J, Wijeratne SS, Hassan YI. Biotin. Biofactors 2009; 35: 36–46.
21. Zempleni J, Mock JM. Bioavailability of biotin given orally to humans in pharmacologic doses. Am J Clin Nutr 1999; 69: 504–508.
22. Zempleni J, McCormick DB, Stratton SL, Lipoic acid (thioctic acid) analogs, tryptophan analogs, and urea do not interfere with the assay of biotin and biotin metabolites by high-performance liquid chromatography/avidin-binding assay. J Nutr Biochem 1996; 7: 518–523.
23. Rulander NJ, Cardamone D, Senior M, Interference from anti-streptavidin antibody. Arch Pathol Lab Med 2013; 137: 1141–1146.
24. Chen T, Hedman L, Mattila PS, Biotin IgM antibodies in human blood: a previously unknown factor eliciting false results in biotinylation-based immunoassays. PLoS One 2012; 7: e42376–e42376.
25. Vos MJ, Rondeel JMM, Mijnhout GS, Immunoassay interference caused by heterophilic antibodies interacting with biotin. Clin Chem Lab. Med Epub ahead of print 1 November 2016 doi:10.1515/cclm-2016-0786.